Core One's Vocan Biotechnologies Incorporates New Bioreactor Equipment Into Production Process Significantly Increasing Throughput of Proprietary Biosynthetic Psilocybin
Core One's Vocan Biotechnologies Incorporates New Bioreactor Equipment Into Production Process Significantly Increasing Throughput of Proprietary Biosynthetic Psilocybin
The new Platform is an extremely efficient platform that can be easily scaled to meet commercial production of Vocan's biosynthetic psilocybin and also be utilized in the production of the subsidiary's other biosynthetic psychedelic compounds.VANCOUVER, BC / ACCESSWIRE / July 11, 2023 / Core One Labs Inc. (CSE:COOL), (OTCQB:CLABF), (Frankfurt:LD6, WKN:A3CSSU) (the "Company") is pleased to announce that its wholly-owned subsidiary Vocan Biotechnologies Inc. ("Vocan") has incorporated a state-of-the-art, high density, fermenting and bio-processing equipment platform (the "Platform") into their proprietary biosynthetic psilocybin (the "Product") production method , significantly optimizing, and scaling up, capacity and product yields, while also increasing purity of the Product.
不列顛哥倫比亞省溫哥華/ACCESSWIRE/2023年7月11日/ Core One實驗室公司(CSE：涼爽的)、(OTCQB：CLABF)、(法蘭克福：LD6、WKN：A3CSSU)(“公司“)很高興地宣佈，其全資子公司Vocan BioTechnologies Inc.(”Vocan)集成了最先進的高密度發酵和生物處理設備平臺(站臺“)轉化為他們專有的生物合成裸蓋菇素(”產品“)生產方法，顯著優化和擴大產能和產品產量，同時還提高了產品純度。
The Company recently announced Vocan's filing of an international patent (see Company's press release dated Friday, July 7, 2023), for the protection of its revolutionary biosynthetic psilocybin production method across many countries. With this patent filing the Company is now rapidly moving towards commercializing its production method. The addition of the Platform is a significant step towards Vocan optimizing its operations to meet the growing demand for psychedelic compounds to be used in pharmaceutical drug formulations. Core One's most efficient path to revenue growth is through the sales of its psychedelic compounds, and scaling up production will allow the Company to move towards achieving these goals.
該公司最近宣佈，Vocan公司申請了一項國際專利(參見公司日期為2023年7月7日星期五的新聞稿)，以保護其革命性的生物合成裸蓋菇素生產方法在許多國家和地區的應用。有了這項專利申請，該公司現在正迅速走向其生產方法的商業化。該平臺的加入是Vocan朝著優化其業務邁出的重要一步，以滿足藥物配方中使用的迷幻化合物日益增長的需求。Core One收入增長的最有效途徑是通過銷售其迷幻化合物，擴大生產將使該公司朝著實現這些目標邁進。
The newly incorporated platform is an integrated, highly scalable manufacturing solution, allowing for streamlined processing development, and subsequent production of Vocan's recombinant biosynthetic psilocybin. The new platform addresses scalability parameters, and significantly reduces the time and resources associated with production. Initial testing of the new platform has evidenced that in addition to productivity optimization, quality of Vocan's biosynthetic psilocybin has also significantly improved.
新合併的平臺是一個集成的、高度可擴展的製造解決方案，允許簡化工藝開發，並隨後生產Vocan的重組生物合成裸蓋菇素。新平臺解決了可伸縮性參數問題，並顯著減少了與生產相關的時間和資源。新平臺的初步測試證明，除了生產率優化外，Vocan的生物合成裸蓋菇素的質量也有了顯著提高。
The new Platform is an extremely efficient platform that can be easily scaled to meet commercial production of Vocan's biosynthetic psilocybin and also be utilized in the production of the subsidiary's other biosynthetic psychedelic compounds.
新的平臺是一個非常高效的平臺，可以很容易地進行擴展，以滿足Vocan生物合成裸蓋菇素的商業生產，也可以用於該子公司的其他生物合成迷幻化合物的生產。
The reduction in cost and lead times to produce biosynthetic psilocybin utilizing the new platform cannot be understated, as the improvements are extremely significant, and will enable Vocan to proceed with commercial production on a large scale much sooner than would have been possible without the new equipment.
利用新平臺生產生物合成裸蓋菇素的成本和交貨期的減少是不可低估的，因為改進是極其顯著的，並將使Vocan能夠比沒有新設備時更快地進行大規模的商業生產。
"I am extremely encouraged with the production efficiencies we are witnessing as a result of our new state-of-the-art production platform," stated Joel Shacker, CEO of the Company. "It is incredible that Vocan's proprietary biosynthetic production method, that was already significantly cost-efficient when compared to traditional synthetic production and extraction methods, has been optimized even further. The continued successes of Vocan scientists in their ability to continually optimize their proprietary production methods, throughput, and purity of product, is significant, and helps to further solidify Core One's position, as market leaders in the development of novel and cost-efficient psychedelics for commercial use," Mr. Shacker, concluded.
“我們新的最先進的生產平臺帶來的生產效率令我深受鼓舞，“該公司首席執行官喬爾·沙克說，”令人難以置信的是，Vocan的專利生物合成生產方法與傳統的合成生產和提取方法相比已經具有顯著的成本效益，但它得到了進一步的優化。Vocan科學家在不斷優化其專有生產方法、產量和產品純度方面的持續成功意義重大，並有助於進一步鞏固Core One作為市場領導者開發用於商業用途的新型和低成本迷幻劑的地位。“謝克先生總結道。
About Core One Labs Inc.
Core One Labs Inc.簡介
Core One Labs Inc. is a biotechnology research and development company focused in life sciences and on bringing psychedelic medicines to market through novel delivery systems and psychedelic assisted psychotherapy. The Company has developed a patent pending thin film oral strip (the "technology") which dissolves instantly when placed in the mouth and delivers organic molecules in precise quantities to the bloodstream, maintaining excellent bioavailability. With this technology, the Company intends to further develop its IP technology to focus on delivering psychedelic molecules with an initial focus on biosynthesized psilocybin. Core One also holds an interest in walk-in medical clinics which maintain a database of over 200,000 patients combined. Through research and development in these clinics, including the integration of its intellectual property related to psychedelic treatments and novel drug therapies, the Company intends to work towards regulatory approval for research that advances psychedelic-derived treatments for mental health disorders.
Core One Labs Inc.是一家專注於生命科學的生物技術研究和開發公司，致力於通過新型給藥系統和迷幻輔助心理療法將迷幻藥物推向市場。該公司開發了一種正在申請專利的薄膜口腔條(“技術”)，該技術在放入口腔時立即溶解，並將精確數量的有機分子輸送到血液中，保持良好的生物利用度。有了這項技術，該公司打算進一步開發其IP技術，專注於交付迷幻分子，最初的重點是生物合成的裸蓋菇素。Core One還對無預約醫療診所感興趣，這些診所維護著一個總共有20多萬名患者的資料庫。通過這些診所的研究和開發，包括整合其與迷幻療法和新型藥物療法相關的知識產權，該公司打算努力爭取監管部門批准對精神健康障礙的迷幻衍生療法進行研究。
Core One Labs Inc.
Core One實驗室公司
Joel Shacker
Chief Executive Officer
喬爾·謝克
首席執行官
FOR MORE INFORMATION, PLEASE CONTACT:
如需更多資訊，請聯繫：
info@core1labs.com
1-866-347-5058
郵箱：Info@core1Labs.com
1-866-347-5058
Cautionary Disclaimer Statement:
謹慎免責聲明：
The Canadian Securities Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of the content of this news release.
加拿大證券交易所沒有對本新聞稿內容的充分性或準確性進行審查，也不承擔任何責任。
Information set forth in this news release contains forward-looking statements that are based on assumptions as of the date of this news release. These statements reflect management's current estimates, beliefs, intentions and expectations. They are not guarantees of future performance. The Company cautions that all forward looking statements are inherently uncertain and that actual performance may be affected by a number of material factors, many of which are beyond the Company's control. Such factors include, among other things: risks and uncertainties relating to the Company's limited operating history and the need to comply with environmental and governmental regulations. Accordingly, actual and future events, conditions and results may differ materially from the estimates, beliefs, intentions and expectations expressed or implied in the forward-looking information. Except as required under applicable securities legislation, the Company undertakes no obligation to publicly update or revise forward-looking information. In addition, psilocybin is currently a Schedule III drug under the Controlled Drugs and Substances Act (Canada) and it is a criminal offence to possess substances under the Controlled Drugs and Substances Act (Canada) without a prescription. Health Canada has not approved psilocybin as a drug for any indication. Core One Labs Inc. does not have any direct or indirect involvement with illegal selling, production, or distribution of psychedelic substances in jurisdictions in which it operates. While Core One Labs Inc. believes psychedelic substances can be used to treat certain medical conditions, it does not advocate for the legalization of psychedelics substances for recreational use. Core One Labs Inc. does not deal with psychedelic substances, except within laboratory and clinical trial settings conducted within approved regulatory frameworks.
本新聞稿中的資訊包含前瞻性陳述，這些陳述基於截至本新聞稿發佈之日的假設。這些陳述反映了管理層目前的估計、信念、意圖和期望。它們並不是未來業績的保證。公司提醒，所有前瞻性陳述本身都是不確定的，實際業績可能會受到許多重大因素的影響，其中許多因素不是公司所能控制的。這些因素包括但不限於：與該公司有限的經營歷史有關的風險和不確定性，以及遵守環境和政府法規的必要性。因此，實際和未來的事件、條件和結果可能與前瞻性資訊中明示或暗示的估計、信念、意圖和預期大不相同。除非適用的證券法規另有要求，否則公司沒有義務公開更新或修改前瞻性資訊。此外，裸蓋菇素目前是《受控藥物和物質法》(加拿大)規定的附表三藥物，根據《受控藥物和物質法》(加拿大)，在沒有處方的情況下擁有物質是刑事犯罪。加拿大衛生部尚未批准裸蓋菇素作為任何適應症的藥物。Core One Labs Inc.不直接或間接參與在其運營的司法管轄區非法銷售、生產或分銷迷幻藥物。雖然Core One Labs Inc.認為迷幻物質可以用於治療某些醫療疾病，但它並不主張娛樂用迷幻物質合法化。Core One Labs Inc.不處理致幻物質，除非在經批准的法規框架內進行的實驗室和臨床試驗環境中。
SOURCE: Core One Labs Inc.
資料來源：Core One實驗室公司
譯文內容由第三人軟體翻譯。